Bryden Considine1, Michael E Hurwitz2. 1. Yale Comprehensive Cancer Center, 333 Cedar Street, New Haven, CT, 06520, USA. 2. Yale Comprehensive Cancer Center, 333 Cedar Street, New Haven, CT, 06520, USA. michael.hurwitz@yale.edu.
Abstract
PURPOSE OF REVIEW: Renal cell carcinoma (RCC) was recognized as an immunologically sensitive cancer over 30 years ago. The first therapies to affect the course of RCC were cytokines (interferon alfa-2B and interleukin-2). Subsequently, drugs that inhibit HIF (hypoxia-inducible factor)/VEGF (vascular endothelial growth factor) signaling demonstrated overall survival advantages (tyrosine kinase inhibitors and mTor inhibitors). RECENT FINDINGS: In the last 3 years, the immune checkpoint inhibitors (ICIs) have become the standard of care treatments in the first and second lines for RCC. Emerging data show that combinations of ICI, HIF signaling inhibitors, and cytokines are potentially powerful regimens. How to combine and sequence these types of therapies and how to integrate new approaches into the management of RCC are now the key questions for the field. Treatment of RCC is likely to change dramatically in the next few years.
PURPOSE OF REVIEW: Renal cell carcinoma (RCC) was recognized as an immunologically sensitive cancer over 30 years ago. The first therapies to affect the course of RCC were cytokines (interferon alfa-2B and interleukin-2). Subsequently, drugs that inhibit HIF (hypoxia-inducible factor)/VEGF (vascular endothelial growth factor) signaling demonstrated overall survival advantages (tyrosine kinase inhibitors and mTor inhibitors). RECENT FINDINGS: In the last 3 years, the immune checkpoint inhibitors (ICIs) have become the standard of care treatments in the first and second lines for RCC. Emerging data show that combinations of ICI, HIF signaling inhibitors, and cytokines are potentially powerful regimens. How to combine and sequence these types of therapies and how to integrate new approaches into the management of RCC are now the key questions for the field. Treatment of RCC is likely to change dramatically in the next few years.
Authors: R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford Journal: N Engl J Med Date: 2001-12-06 Impact factor: 91.245
Authors: R A Figlin; J A Thompson; R M Bukowski; N J Vogelzang; A C Novick; P Lange; G D Steinberg; A S Belldegrun Journal: J Clin Oncol Date: 1999-08 Impact factor: 44.544
Authors: K Kondo; M Yao; K Kobayashi; S Ota; M Yoshida; S Kaneko; M Baba; N Sakai; T Kishida; S Kawakami; H Uemura; Y Nagashima; Y Nakatani; M Hosaka Journal: Int J Cancer Date: 2001-01-15 Impact factor: 7.396
Authors: Christine C Hudson; Mei Liu; Gary G Chiang; Diane M Otterness; Dawn C Loomis; Fiona Kaper; Amato J Giaccia; Robert T Abraham Journal: Mol Cell Biol Date: 2002-10 Impact factor: 4.272
Authors: James C Yang; Richard M Sherry; Seth M Steinberg; Suzanne L Topalian; Douglas J Schwartzentruber; Patrick Hwu; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Donald E White; David J Liewehr; Maria J Merino; Steven A Rosenberg Journal: J Clin Oncol Date: 2003-08-15 Impact factor: 44.544
Authors: M Hecht; S Semrau; M Beck; J Hartwich; M Eckstein; D Schmidt; A O Gostian; S Müller; S Rutzner; U S Gaipl; J von der Grün; T Illmer; M G Hautmann; G Klautke; J Döscher; T Brunner; B Tamaskovics; A Hartmann; H Iro; T Kuwert; R Fietkau Journal: Ann Nucl Med Date: 2022-05-10 Impact factor: 2.258
Authors: Michael Friedrich; Christine Stoehr; Simon Jasinski-Bergner; Arndt Hartmann; Sven Wach; Bernd Wullich; André Steven; Barbara Seliger Journal: J Transl Med Date: 2020-09-29 Impact factor: 5.531
Authors: Maria F Czyzyk-Krzeska; Julio A Landero Figueroa; Shuchi Gulati; John T Cunningham; Jarek Meller; Behrouz ShamsaeI; Bhargav Vemuri; David R Plas Journal: Genes (Basel) Date: 2021-03-09 Impact factor: 4.096